The decline of smoking among Swedish men.

BACKGROUND: In 1987 the Association of the Nordic Cancer Registers (ANCR) predicted the incidence of lung cancer in the Nordic countries up to the years 2000 and 2010. The predictions for Sweden can now be considered against recent information on smoking habits. METHODS: Regular, question-based studies on the public's tobacco consumption are carried out by four separate institutions in Sweden. This article summarizes and updates the smoking habits among Swedish men in the age groups 35-54 and 55-70 years between 1963 and 1994, with special focus on smoking cessation. RESULTS: Between 1963 and 1994, there was a significant and continuous decrease in the prevalence of smoking among Swedish men. During this time ex-smoking men increased from 20% to 41%. The data reveal a continuous, unbroken and uniform increase in smoking cessation rates during the last 20 years, despite the small success of smoking cessation programmes and smoking-relapse rates of 75-80%. The explanation of this seems to be the surprisingly high frequency of smokers who attempted to stop smoking each year (about 30%). The best success rate in smoking cessation was achieved by occasional smokers and others with a low cigarette consumption. CONCLUSION: With the continuing fall in the numbers of smoking men, a greater drop in lung cancer incidence than predicted by the ANCR in 1987 may be expected in Sweden within the coming decade.

Subcutaneous interleukin-2 and alpha-interferon in advanced colorectal carcinoma. A phase II study.

Subcutaneous administration of low doses of recombinant interleukin-2 (IL-2) and interferon-alpha (IFN-alpha) on an out-patient basis has been reported not to significantly compromise the response frequency compared to intravenous IL-2 in patients with renal cell carcinoma and melanoma. As part of an ongoing program to develop a biotherapeutic concept in patients with colorectal carcinoma (CRC) we studied the clinical effects of such a regimen in 15 patients with metastatic CRC. The daily dose of IL-2 varied between 4.8-14.4 x 10(6) U/m2 and of IFN-alpha between 3-6 x 10(6) U/m2. The cycle length was 6 weeks. The course was repeated every 8 weeks until disease progression. Maximum 4 cycles were administered. Maintenance therapy was given to responding patients once a week every month. No patient showed a major response (CR or PR). Six patients had a stable disease ranging from 3 months to 18 months with a median duration time of 5 months. The median survival of all patients was 13 months. The main adverse reactions were fever, chills, anorexia and shortness of breath. No treatment related deaths occurred. 6/14 patients developed abnormal concentration of serum levels of thyroid hormones. It is concluded that the present treatment schedule using IL-2 and IFN-alpha in advanced CRC seemed not to be of clinical benefit.

Low dose cyclophosphamide, alpha-interferon and continuous infusions of interleukin-2 in advanced renal cell carcinoma.

Pretreatment with a low dose of cyclophosphamide (CY) has been claimed to inhibit suppressor functions and augment various immune functions. A combination of a low dose of CY, alpha-interferon (IFN-alpha) and continuous infusion of interleukin-2 (IL-2) was used to treat patients with advanced renal cell cancer (RCC) (stage IV). Sixteen patients received four cycles consisting of CY (500 mg m-2) three days prior to daily i.m. injections of alpha-IFN (3 x 10(6) U), and continuous infusion of 18 x 10(6) IU rIL-2 for five days. The cycle interval was three weeks. Two patients had partial response (13%) (26+ and 12+ months), two had a minor response (9+ and 4 months), and three patients achieved stable disease (19+, 14+ and 8+ months). No patients required intensive care. Side effects were mainly fever, malaise, capillary leak syndrome and diarrhoea. Non-responders showed significantly higher eosinophil and platelet counts compared to responders. Serum concentration of IL-2 was significantly higher in responders. 5/11 patients had abnormally low values of serum thyroxine after therapy. Two patients needed thyroid hormone substitution. The difference between the initial and the lowest thyroxine values correlated significantly to survival (p < 0.03). The addition of CY to rIL-2 and IFN-alpha in the present protocol did not contribute to an increased major response rate.